

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>AH Bio Fund IV, L.P.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Braveheart Bio, Inc. [BRVE]</u> Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>08/07/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director ☒ 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person ☒ Form filed by More than One Reporting Person
---	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/07/2026		C		9,132,420	A	(1)	9,132,420	I	By AH Bio Fund IV, L.P. ⁽²⁾ (3)
Common Stock	08/07/2026		P		1,100,000	A	\$18	10,232,420	I	By AH Bio Fund IV, L.P. ⁽²⁾ (3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	08/07/2026		C		40,000,000	(1)	(1)	Common Stock	9,132,420	\$0	0	I	By AH Bio Fund IV, L.P. ⁽²⁾⁽³⁾

1. Name and Address of Reporting Person* <u>AH Bio Fund IV, L.P.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>AH Equity Partners Bio IV, L.L.C.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)
1. Name and Address of Reporting Person*

Andreessen Marc L

(Last) (First) (Middle)
C/O ANDREESSEN HOROWITZ
2865 SAND HILL ROAD, SUITE 101

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)

1. Name and Address of Reporting Person*
HOROWITZ BENJAMIN A

(Last) (First) (Middle)
C/O ANDREESSEN HOROWITZ
2865 SAND HILL ROAD, SUITE 101

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)

Explanation of Responses:

1. Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.

2. The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.

3. (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

AH Bio Fund IV, L.P., By AH
Equity Partners Bio IV, L.L.C.,
Its General Partner, By /s/ Phil 08/11/2026
Hathaway, Chief Operating
Officer

AH Equity Partners Bio IV,
L.L.C., By /s/ Phil Hathaway, 08/11/2026
Chief Operating Officer

/s/ Phil Hathaway, Attorney-in-
Fact for Marc L. Andreessen 08/11/2026

/s/ Phil Hathaway, Attorney-in-
Fact for Benjamin Horowitz 08/11/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.